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Abstract: Two self-associating biopolymers, namely chitosan (Ch) and a high-molar-mass hyaluronan
(HA), were used to prepare membranes with the aim to protect and to enhance the healing of
injured skin. A mitochondrially-targeted antioxidant—MitoQ—was incorporated into the mixture of
biopolymers prior to their self-association. These three-component membranes were evaluated in
detail utilising surface roughness measurements, contact angle measurements, hemocompatibility,
and thrombogenicity analyses. Furthermore, in vivo application of Ch/HA/MitoQ membranes was
assessed on injured rabbit and rat skin utilizing histological methods. The results showed that the
prepared thrombogenic Ch/HA/MitoQ membranes had higher roughness, which allowed for greater
surface area for tissue membrane interaction during the healing processes, and lower cytotoxicity
levels than controls. MitoQ-loaded composite membranes displayed superior healing properties in
these animal models compared to control membranes.
Keywords: mitochondrially-targeted antioxidant; skin wounds; hyaluronan; chitosan
1. Introduction
Oxidative damage is associated with aging and a wide range of human disorders [1]. Production
of reactive oxygen species (ROS), such as superoxide anion radical O2•– and the oxidant H2O2, occurs
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during cellular respiration in mitochondrion. Healthy young cells are capable of detoxifying ROS
using enzymes such as superoxide dismutases and catalase [2–4].
Damaged tissues, such as leg and decubitus ulcers or severe burns, often undergo acute and,
subsequently, chronic inflammation. These tissues contain necrotic cells and cells in which oxygen
uptake is insufficient due to damage of extracellular glycocalyx (state of hypoxia). It is well known that
mitochondria in cells enhance the production of ROS, such as O2•– and H2O2 forming •OH radicals
during hypoxia, and damaged cells are incapable of repair [5,6]. In general, it is known that ROS
originate in elevated amounts from stressed cells. Therefore, it is favourable to limit the production of
ROS in a site of chronic inflammation.
One way to effectively reduce an adverse flow of ROS from mitochondria is to use mitochondria
targeted antioxidants (MTAs), which selectively enter mitochondria. Presently, MTAs are applied at
the site of inflamed tissue at relatively low concentration for a prolonged period of time. The main
requirement for the function of an antioxidant as a protective species for mitochondria is its capacity
to penetrate through the cell-cytosolic-bilayer and to enter into the subcellular compartments, namely
to the space between the inner and outer mitochondria membranes (lipid bilayers) and into the matrix
of the mitochondrion [7].
In recent years, research has focused on the advancement of mitochondria-targeted antioxidants,
such as MitoQ, the molecule which is composed of the coenzyme Q10 carried by the lipophilic
triphenylphosphonium cation, often classified as the Skulatchev ion [8]. Due to its lipophilic tail,
MitoQ migrates to the cell cytosolic membrane, diffuses through it easily, and accumulates in relatively
high concentrations within mitochondria [9–14].
MitoQ exists in two forms: the oxidized form MitoQuinone and the reduced one MitoQuinol [15].
The drug active principle is related to coenzyme Q10, which serves as the donor-acceptor of
electrons [16]. Since HA bears a negative charge and chitosan a positive one, the complexation
of these two biopolymers results in the formation of stable composite membranes. Through setting an
optimal ratio of Ch and HA, it is postulated that the rate of MitoQ release from the Ch/HA/MitoQ
composite membranes may be controlled.
HA hydrogels are largely utilised in drug delivery, tissue engineering, and wound
dressing applications, mainly due to their high water-retaining capacity, stability, biocompatibility,
and tuneable viscoelastic properties [17]. During the inflammatory phase of wound healing endogenic
high-molar-mass HA accumulates in the wound and functions as a regulator of early inflammation.
The major functions of HA in this phase are the modulation of inflammatory cells and fibroblast cell
migration, modulation of the synthesis of proinflammatory cytokines, and phagocytosis of invading
microorganisms. In this phase, HA degradation products, such as low-molar-mass HA (2.5 × 105 Da),
can enhance early inflammation [18,19]. The HA fragments, which accumulate due to degradation of
high-molar-mass HA, can initiate toll receptor-2 and toll receptor-4 induction of pro-inflammatory
cytokines IL-6, TNF-α, and IL-1β. The proliferative phase overlaps with the remodelling phase,
where keratinocytes differentiate to fibroblasts. During these phases the growth factors and cytokines
released by the inflammatory cells induce fibroblast and keratinocyte migration and proliferation. In the
second and third phases of healing endogenic HA binds with water, thereby contributing to a moist
environment [20]. The levels of HA synthesized by both fibroblasts and keratinocytes are elevated
during re-epithelisation where epithelial cells migrate across the new tissue to form a barrier between the
wound and the environment [21]. As a result, HA is involved in the healing of acute wounds, accelerates
healing of chronic skin damage, diabetic ulcers, and decubites [22–25]. HA has also been used as a
coating to enhance cellular viability on synthetic tissue scaffolds [26].
Chitosan positively influences the healing process through faster formation of granular tissue
in the initial stages of healing [27–30] with chitosan and its derivatives displaying antioxidative and
antibiotic behaviour [31].
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Although Ch/HA membranes have been used previously for wound healing [32], this paper
focuses on the influence of MitoQ on the healing process in rabbit and rat models. The influence of
MitoQ incorporation on the physico-chemical properties of the membranes is also determined.
2. Experimental
2.1. Materials and Animals
Chitosan of molar mass 100–300 kDa was obtained from ACROS Organics™ (Geel, Belgium).
Hyaluronan (sodium salt) with a mean molar mass of 500.0 kDa was obtained from Contipro
(Dolni Dobrouc, Czech Republic). NaOH, ethanol, acid citrate dextrose solution (ACD), calcium chloride
solution, MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, dimethyl sulfoxide (DMSO),
phosphate-buffered saline solution (PBS), formaldehyde solution, trypane blue, diethyl ether, formalin,
and haematoxylin and eosin were purchased from Sigma-Aldrich (St. Louis, MO, USA). MitoQ was a gift
from the Medical Research Council Mitochondrial Biology Unit (Cambridge, United Kingdom).
Nine crossbred male rabbits HIL (2.5 ± 0.5 kg) from the Department of Toxicology and Breeding
of Laboratory Animals at the Institute of Experimental Pharmacology and Toxicology in Dobra Voda,
Slovakia were used. Fifteen adult female Wistar rats (230–250 g) were purchased from the Egyptian
Company for Biological Products and Vaccines (VACSERA), Helwan, Cairo, Egypt.
2.2. Composite Membrane Production
Membranes were prepared as follows: chitosan (0.5 g) was dissolved in 20 mL of aqueous acetic acid
(2%, v/v). Hyaluronan (50 mg) was dissolved overnight (16 h) separately in 4 mL of water in accordance
with Collins et al. (2013) [33]. Both solutions were then mixed together, and 1 mL of the aqueous stock
MitoQ solution (1.47 mg/mL) was admixed into the homogeneous chitosan-hyaluronan solution. Next,
1 mL of glycerol was added into the chitosan-hyaluronan-MitoQ solution to function as a plasticizer.
The multicomponent solution with a total volume of 25 mL was cast on a clean Petri dish (diameter = 7 cm)
and the solvent was allowed to evaporate at room temperature over 48 h. The dry membrane, which
was separated from the Petri dish, was rinsed for approx. 30 s in the aqueous NaOH solution (1 M).
During this procedure, the traces of acetic acid, still adsorbed on the membrane, were removed thoroughly.
The membrane was then washed for approx. 2 min in distilled water. Finally, the wet membrane was
spread out and attached to a clean glass support with clamps, and allowed to dry for 24 h at room
temperature. Prepared membranes were held between two polyethylene sheets and stored in a refrigerator
(4 ◦C). The following membranes types were prepared: one without MitoQ (Ch/HA) and the other one
containing MitoQ (Ch/HA/MitoQ). Before applying them to the rat skin, membranes were sterilized by
spraying them with 70% aqueous ethanol, and dried under a UV lamp for 20 min.
2.3. Membrane Characterisation
Measurements of a static water contact angle were performed at room temperature using advanced
500-F1 model goniometer in a sessile drop configuration (using ultrapure water as the liquid), coupled
with a video camera and image analysis software. At least ten droplet images were obtained for each
membrane surface.
Approval was received from all volunteers before the use of their blood for assessment of
compatibility and cytotoxicity. The human blood was used according to the Research Ethical
Committee (REC) which was published by the National Health and Medical Research Council
policies and the recommendations of Ministry of Health and Population, High Committee of Medical
Specialties, Egypt. This current research was granted permission by City of Scientific Research and
Technological Application (SRAT-City).
The membrane surface roughness was measured using a surface roughness tester (SJ-201P,
Mitutoyo Corp., Kanagawa, Japan). Membranes were fixed onto a glass slide with double-sided
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tape. The dimensions of samples were 25 mm × 25 mm. All recorded results are the average of
triplicate measurements.
Scanning electron microscopy equipped with energy dispersive spectroscopy (EDS) (JEOL Jsm
6360LA, Jeol Ltd., Tokyo, Japan) was utilized to analyse samples which were fixed on a specimen mount
using carbon paste. All samples were coated with a thin layer of gold to eliminate charging effects.
EDS was used to identify MitoQ in the final membranes through the identification of phosphorus
atoms. Mechanical properties were measured according to ASTM D-882 using a universal testing
machine (AG-1S Shimadzu, Schimadzu Corp., Tokyo, Japan). Membrane thickness was obtained with
an electronic digital micrometer (Shenzhen Pride Instrument Inc., Guangdong, China).
2.4. Evaluation of Hemocompatibility of Membranes
Hemolysis tests were performed as described in American Society for Testing and Materials
(ASTM) (ASTM F 756-00, 2000) (US Pharmacopeia XXIII, 1994). Anticoagulated blood was used for
this purpose. This sample was prepared by adding 1 mL of anticoagulant acid citrate dextrose solution
(ACD) to 9 mL of fresh human blood. Before performing the tests, the membranes (1 cm2) were placed
in polypropylene test tubes, and 7 mL of PBS (pH 7.0) were added. After 72 h of incubation at 37 ◦C,
PBS was removed, and 1 mL of ACD blood was added to each sample and maintained at 37 ◦C for 3 h.
Positive and negative controls were prepared by adding the same amount of ACD blood to 7 mL of
water and PBS, respectively. Each tube was gently inverted twice each for 30 min to maintain contact
of the blood with the material. After incubation, each fluid was transferred to a suitable tube and
centrifuged at 2000 rpm for 15 min. The hemoglobin released by hemolysis was measured by the
optical densities (OD) of the supernatants at 540 nm using a spectrophotometer (Pharmacia Biotech
Ultrospec 2000, Lab Wrench, Midland, ON, Canada).
The percentage of hemolysis was calculated as follows:
Hemolysis (%) = [(ODsample − ODnegative control)/(ODpositive control − ODnegative control)] × 100 (1)
According to ASTM F 756-00 (2000), materials can be classified into three different categories
based on their hemolytic index (%): (i) materials with percentages of hemolysis over 5% are considered
hemolytic; while the ones with (ii) a hemolytic index between 5% and 2% are classified as slightly
hemolytic. Finally, when the material presents (iii) a hemolysis percentage below 2%, it is considered
as a non-hemolytic material.
2.5. Thrombogenicity of Membranes
Evaluation of thrombus formation on polymeric surfaces was carried out using a gravimetric
method [34]. Anticoagulated fresh human blood was used for this purpose, as mentioned above.
Before performing the tests, samples were immersed in PBS at a constant temperature of 37 ◦C. After 48 h
of incubation, PBS was removed and ACD blood was put in contact with the surface of the tested
membranes and also to the empty Petri dish, which acted as a negative control. Blood clotting tests
were initiated by adding 20 µL of a 10 M calcium chloride solution and were stopped after 45 min by
the addition of 5 mL of water. Resultant clots were fixed with 5 mL of a 36% formaldehyde solution
and were then dried with a tissue paper and finally weighed. Each test was carried out in triplicate and
mean values were calculated.
2.6. Determination of Toxicity against Human Peripheral Blood Mononuclear (PBMC) Cells
The cytotoxic effect of different compound concentrations on normal human cell growth was
determined using an MTT assay. Peripheral blood mononuclear cells (PBMC) were isolated using
the Ficoll-Hypaque density gradient centrifugation method. Fresh heparinized blood was mixed
with an equal volume of PBS, slowly layered over an equal volume of the Ficoll-Hypaque solution
(density = 1.077 g/mL) and centrifuged for 30 min at 2000 rpm. The PBMC at the buffy layer was
collected, resuspended in PBS, and centrifuged for 5 min at 1650 rpm. Cells were resuspended in RPMI
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1640 containing 10% FBS (GIBCO, Waltham, MA, USA), counted, and viability was determined by
staining with 0.5% trypan blue and counting on a hemocytometer (manufacturer, city, state, country).
Mononuclear cells (1× 106 cells/mL) were resuspended gently in RPMI medium (Lonza, Morristown,
NJ, USA) containing 10% FBS and the cell count was adjusted to 1 × 105 cells per 1 mL of the selected
culture medium. The 1× 105 mononuclear cells were seeded in each well of the 96-well microtitre plate.
Cells were treated with and without membranes of varying weights (4 and 5 mg) and wells containing only
a complete medium were used as controls. After 72 h of incubation in a 5% CO2 incubator (Sanyo Electric
Biomedical Co., Ltd., Osaka, Japan), 20 µL of MTT solution (5 mg/mL in PBS, pH 7) was added to each
well and incubated at 37 ◦C for 4 h. The MTT solution was removed after centrifugation at 2000 rpm for
10 min and the insoluble blue formazan crystals trapped in cells were solubilized with 150 µL of 100%
DMSO at 37 ◦C for 10 min. The absorbance of each well was measured with a microplate reader at 570 nm.
2.7. Ischemic Wound Healing in Rabbits
Experiments were approved by the ethical committee of the Institute of Experimental Pharmacology
and Toxicology in Bratislava, Slovakia (SK P 23011), followed by the State Veterinary and Food
Administration in Bratislava, Slovakia (2267/16-221). Ischemic wounds on rabbits’ ears were performed
according to DiPietro’s method [35]. Inside of each rabbit’s ear, two lacerations with a size of ca. 1 cm× 1 cm
and a complete removal of skin tissue were performed. Rabbits were divided into three groups of three
animals: first group—control (wound was covered with bandage); second group—animals treated with
Ch/HA membrane; and third group—animals treated with Ch/HA/MitoQ membrane. After operation
animals had a standard post-operational care. Animals were administered analgesics during the study.
Rabbits were maintained individually in cages with an area of 4200 cm2 in daily 12 h light-dark cycles.
Animal wounds were covered with dehydrated membranes immediately after primary treatment
of wounds. Each membrane was moisturized in saline and disinfected with 80% ethanol. During
15 day-experiment membranes were replaced with new ones after 3, 6, 9, and 12 days. Wounds in
control animals were only washed with saline and in treated animals membranes were fastened to
wounds with standard plasters. Wounded ears of all animals were bandaged. During this process
animals were under anaesthesia.
The efficacy of Ch/HA and Ch/HA/MitoQ membranes on healing of wounds was evaluated
on the 3rd, 6th, 9th, 12th, and 15th day of the experiment through measuring the area of wounds.
To statistically evaluate the percentage of healing in injured ischemic tissue, we used an ANOVA test.
Results are shown as the average and standard deviation for each group of animals. Macroscopic
morphology was evaluated from photographs.
2.8. Wound Healing in Rats
The animal study was performed following the guidelines stipulated by the local committee
of the Egyptian Academy of Scientific Research and Technology (ASRT) based on the protocols and
instructions of the National Institutes of Health (Institute of Laboratory Animal Resources 1996)
in the Faculty of Medicine, Alexandria University, Egypt. Rats were divided randomly into three
groups with seven animals in each (five animals were analysed and two animals were sacrificed for
histological study): group 1 where the wound was dressed directly with Ch/HA membrane followed
by gauze and plaster; group 2 where the wound was dressed directly with Ch/HA/MitoQ membrane
followed by gauze and plaster; and group 3 was the negative control, where the wound was covered
with commercial cotton gauze supplied by El-Gomhouria Co. Cairo, Egypt and commercial plaster.
After being anesthetized, their dorsal fur was shaved with an electric razor. The dorsum of rats was
disinfected with 70% ethanol and wounds were created (1.5 cm × 1.5 cm). After being dressed with
different membranes, which were previously sterilized in 70% ethanol and by UV lamp for 20–30 min,
plasters were put on the dorsum and the whole abdomen of the rats. Bandages were used for fixing
the dressing materials. Rats were kept separately in disinfected polypropylene cages and maintained
for three weeks at 25 ◦C, as well as subjected to natural light for 12 h and dark for 12 h. The bandages
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were changed with a new membrane every three days until day 10. After 10 days of experiments,
the bandages were changed only with gauze and plaster without adding any new membranes in the
three groups. Wounds were cleaned with PBS after each membrane change. The healing wounds were
observed and photographed using a digital camera on the 0th, 7th, 14th, and 21st day after surgery.
With, the size of the healing wound determined and analysed using Image J software. The percentage
of wound healing was estimated by using the following formula:
Wound healing (%) = 1 − (wound area day/wound area day 0) × 100 (2)
All membranes were kept in a humidity chamber (37 ◦C and humidity 50%) for at least 6 h before
being applied to the wound.
2.9. Histological Examination of Wounds
Rats were sacrificed after the 7th, 14th, and 21st day, rabbits were sacrificed after the 15th day,
and the wound areas, as well as the surrounding skin, were harvested for histological examinations.
The tissues were immediately fixed in 4% formalin, then treated with conventional ethanol gradient
dehydration and embedded in paraffin blocks. The tissues were sectioned into 6 µm thickness
and stained with haematoxylin and eosin. Samples were subsequently observed under an optical
microscope (Olympus, Tokyo, Japan).
3. Results and Discussion
3.1. Identification of MitoQ within Membranes
In order to establish if the MitoQ was successfully incorporated within the Ch/HA membranes,
membranes which were subjected to the MitoQ loading regime were studied by EDS. Figure 1 clearly
shows the EDS spectrum of membranes with and without MitoQ. Membranes containing MitoQ
displayed phosphorous (~2.64%) which confirmed that MitoQ was successfully incorporated in those
membranes. The absence of phosphorus in the control membranes confirmed the result.
Figure 1. Cont.
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Figure 1. EDX spectrum of (a) Ch/HA and (b) Ch/HA/MitoQ membranes.
3.2. Membrane Characterization
The contact angles of Ch/HA and Ch/HA/MitoQ membranes were recorded as 70.1 ± 0.48◦ and
77.4 ± 0.47◦, respectively. Ch/HA membranes became more hydrophilic than chitosan membranes
(contact angle of pure chitosan film was 89 ± 0.6◦). An increase in membrane hydrophobicity is
associated with MitoQ loading. Additionally, the roughness of membranes increased from 1.1 ± 0.12
to 1.23 ± 0.31 µm, as a result of MitoQ addition.
One of the most important conditions for enhancing the wound healing process is the existence
of a moist environment over the wounded site. Dressing agents that provide a moist burn or wound
environment boost the healing process via augmenting cell migration to the injured area and these cells
aid tissue regeneration. Additionally, the hydrophobicity and roughness of the membranes prevent
water absorption from the wound aiding the overall healing process.
There is also evidence of a slight increase in hemolysis (2.2 ± 0.14% to 2.3 ± 0.28%) by MitoQ
containing membranes. With respect to thrombogenicity, blood clots were 0.821 ± 0.021 and
0.927 ± 0.012 g for Ch/HA and Ch/HA/MitoQ, respectively. The clots associated with the membranes
were larger than those associated with the negative control (blood without membranes) which were
0.729 ± 0.021 g. For this reason the membranes can be classified as thrombogenic [34].
Cytotoxicity of Ch/HA and Ch/HA/MitoQ on normal human cell growth was measured and
listed in Table 1. Cell viability reduced as a function of membrane weight and improved with
incorporation of MitoQ into the membranes.
Table 1. Cytotoxicity studies of Ch/HA and Ch/HA/MitoQ membranes.
Cell Viability [%]
Sample Weight (mg) Ch/HA Ch/HA/MitoQ
5 80.62 ± 2.3 86.69 ± 4.4
4 85.16 ± 2.8 98.69 ± 5.7
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Figure 2 shows the morphology of Ch/HA and Ch/HA/MitoQ membranes. Incorporation of
MitoQ inside membranes shows increased surface roughness. This is explained by MitoQ-induced
crystal structure distortion and elimination of intermolecular bonds. The increased surface roughness
of membranes will help achieve a favourable interaction between the membranes and biological tissues.
Figure 2. SEM images of (a) Ch/HA and (b) Ch/HA/MitoQ membranes.
Mechanical properties of membranes with and without MitoQ are shown in Table 2. The
tensile strength of Ch/HA membranes is attributed to the intermolecular hydrogen bonds between
hydroxyl and amine groups in chitosan and the hyaluronan backbone and polyelectrolyte interaction
between carboxylic and amine groups. Addition of MitoQ demonstrates a reduction in mechanical
properties which may be attributed to a plasticization effect; a similar trend was shown in caprolactones
upon additive addition [36,37] or the interruption of chain-chain intermolecular bonding. Overall,
the mechanical measurements show that MitoQ molecules slightly disturb the membrane formation
which occurs through polyelectrolyte ion-pair interactions as the resistance at break is slightly reduced.
Table 2. Mechanical properties of Ch/HA and Ch/HA/MitoQ membranes.
Max Stress σmax (N/mm2) Max Strain λmax % Energy–Max (J)
Ch/HA 34.06 ± 1.9 n = 3 4.9 ± 1.7 n = 3 0.04 ± 0.01 n = 3
Ch/HA/MitoQ 22.0 ± 1.6 n = 3 5.04 ± 1.5 n = 3 0.01 ± 0.01 n = 3
3.3. Reepithelization of Ischemic Wounds in Rabbits
The prepared membranes were applied on two animal models: rats and rabbits. Two animal
models were used, as rats are a model for healthy animals and rabbits with ear ischemia are a model
for animals with disease. As seen in Figure 3 a, b results of measuring areas of wounds after three days
showed only mild shrinking of the wound area in untreated control animals. On the contrary, in rabbits
treated with Ch/HA and Ch/HA/MitoQ membrane faster healing was observed. On the 6th day a
significantly faster re-epithelisation of treated skin wounds was seen compared to the control group.
Re-epithelisation of the tissue in the control group of animals was observed on the 9th day of the
study. After 12 days the process of wound healing accelerated in all groups, especially in treated ones.
In untreated animals the percentage of shrinking wounds after 15 days reached 81% while, in treated
animals, the percentage of wound healing was over 90% with some wounds completely healed or
re-epithelised. It can be concluded that the fastest re-epithelisation was observed in wounds covered
with Ch/HA/MitoQ composite membranes. Ch/HA membranes were shown to be less effective in
healing rabbits’ wounds.
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Figure 3. Profiles of the wound closures in rabbits, when the wound was not treated (control),
the wound treated with the Ch/HA membrane and the Ch/HA/MitoQ membrane. The asterisk
(*) indicates a significant difference at p ≤ 0.05 between the control and Ch/HA/MitoQ. The mark
(#) indicates a significant difference between the Ch/HA and Ch/HA/MitoQ membranes at p ≤ 0.05.
The mark ($) indicates a significant difference between the control and the Ch/HA membrane at
p ≤ 0.05, n = 6 (a,b).
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In the control group maturating granular tissue with the prevalence of leukocytes, lower amount
of histiocytes, perpendicular distribution of fibroblasts, and hyperemic capillaries with perivascular
bleeding can be observed, with corresponding images of wound contraction in rabbits at the 0th, 3rd,
6th, 9th, 12th, and 15th day after injury in the control group and groups covered with Ch/HA and
Ch/HA/MitoQ membranes.
In the skin wound treated with the Ch/HA membrane we can see maturating granular tissue and
it is expected that this would be composed predominantly of macrophages, plasmocytes, leukocytes,
fibroblasts, and myxoid changes of the stroma due to the presence of acid mucopolysaccharides.
As shown in Figure 4, the wound treated with the Ch/HA/MitoQ membrane is a healed skin
defect that is likely composed of maturated granular tissue with histiocytes, and small amounts
of leukocytes, fibroblasts, and myxoid changes in the stroma may be due to the accumulation of
acid mucopolysaccharides.
Figure 4. Histology of skin wounds in rabbits after 15 days of treatment. (a) Control: star—vascular
granular tissue; (b) Ch/HA membrane: arrow—likely site of activated fibroblasts with formation of
collagen fibres (it is acknowledged that a Masson trichrome or immunostaining is required to accurately
identify these entities), star—newly-formed veins; (c) Ch/HA/MitoQ membrane: star—nonspecific
granular tissue in the initial stage with enhanced cellularity.
3.4. Experiments In Vivo in Rats
Wound closure percent was calculated and is illustrated in Figure 5a. Photographs of the full
layer wounds treated with Ch/HA and Ch/HA/MitoQ composite membranes and control (gauze)
dressings during 0–21 days after injury are shown in Figure 5b. Both Ch/HA and Ch/HA/MitoQ
dressings kept the wounds moist. At the day of surgery, no noticeable variation in a wound
appearance was noted for all groups. On the 7th day it is clear both Ch/HA and Ch/HA/MitoQ
dressing promoted the fastest healing. On the 14th day, wounds treated with the Ch/HA/MitoQ
were almost healed. On the 21st day, the damaged skin was entirely healed for the dressing with
Ch/HA/MitoQ composite membranes. Visual observations indicate that the Ch/HA membranes act
as efficient wound healers and their performance can be further enhanced through the incorporation
of mitochondrially-targeted antioxidant—MitoQ.
3.5. Histological Observation
Figure 6 shows the histological analysis of injured tissue treated with Ch/HA and Ch/HA/MitoQ
membranes compared with the untreated wound (control) at different times after injury. Recovery of
tissue was clearly observed with CH/HA/MitoQ membranes at all time intervals. Positive control
(Ch/HA) showed significant healing comparing to the negative control (gauze). The control group
had a significantly higher number of inflammatory cells than that one treated with membranes of
any type, i.e., with or without MitoQ. Efficient healing was verified by the presence of hair follicles,
and matured fibrous tissues for membranes containing MitoQ.
Traditional treatment of acute wounds using gauze only (as in the control group here) exhibited
incomplete healing during the study period. Applying Ch/HA membranes to the wound demonstrated
an improvement in wound healing compared to the control and this is attributed to faster migration of
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epithelium cells to replace dead cells. For composite membranes (i.e., Ch/HA/MitoQ) the histology of
rat skin preparations showed significant development in the initial healing step when compared to
both the negative control (gauze) and the positive control (Ch/HA membrane). This observation can
be attributed to the MitoQ control of wound inflammation during the initial healing phase.
Figure 5. Profiles of the wound closures in rats, when the wound was not treated (control), the wound
treated with the Ch/HA membrane, and the Ch/HA/MitoQ membrane; and the asterisk (*) indicates
a significant difference at p ≤ 0.05 between the control and Ch/HA/MitoQ). The mark (#) indicates a
significant difference between the Ch/HA and Ch/HA/MitoQ membranes at p ≤ 0.05. The mark ($)
indicates a significant difference between the control and the Ch/HA membrane at p ≤ 0.05, n = 5 (a,b).
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Figure 6. Histology of wounds treated with control (gauze), Ch/HA, and Ch/HA/MitoQ membranes
at the 7th, 14th, and 21st day after the injury. Epi: Epidermis; K: keratinous layers; IC: possible site of
inflammatory cells; BV: blood vessels; HF: hair follicles; SG: sebaceous glands.
4. Conclusions
These carbohydrate polymers (Ch and high-molar-mass HA) are known to have a beneficial effect
on the healing process and induction of homeostasis in organisms. Here, it has been demonstrated
that the Ch/HA/MitoQ composite membrane, when subjected to physical-chemical and mechanical
tests, displayed different properties compared to the Ch/HA membrane only. When demonstrated
on injured rabbit and rat skin the membranes were remarkably efficient, and accelerated the healing
process mainly through an inflammation suppression mechanism. The results reported here of in vivo
experiments show the potential of using MitoQ—an MTA substance—for the treatment of skin
tissue wounds.
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